Stock comparison
Arbutus Biopharma
ABUS$892.87MHealthcare Market cap, Sector
Pro Medicus Limited
PME.AX$18.81BHealthcare Market cap, Sector
Overall winner
Pro Medicus Limited
ABUS 16 PME.AX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
ABUS1wins
6winsPME.AX
49D
B78
43F
A90
55D
A98
48D
A100
100A
B84
64C
A91
66C
A96
Side-by-side metrics
| Metric | ABUS | PME.AX |
|---|---|---|
| Market cap | $892.87M | $18.81B Winner |
| P/E (TTM) | Winner: 5.1x | 147.6x |
| EV/EBIT | Winner: - | 106.8x |
| ROIC (TTM) | Winner: 56.72% | 42.56% |
| Gross margin | Winner: 99.98% | 99.85% |
| Net margin | Winner: 83.95% | 54.12% |
| Revenue CAGR 5y | 6.4% | 31.61% Winner |
| EPS CAGR 5y | - | 37.34% |
| Debt / Equity | Winner: 0.0x | 0.0x |
| Dividend yield | 0.0% | - |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ABUS leads on
- EV/EBIT-vs 106.8x+128%
- P/E (TTM)5.1xvs 147.6x+97%
- Debt / Equity0.0xvs 0.0x+72%
- Net margin83.95%vs 54.12%+36%
PME.AX leads on
- Market cap$18.81Bvs $892.87M+95%
- Revenue CAGR 5y31.61%vs 6.4%+80%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.